Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
onvansertib + FOLFIRI + bevacizumab arm produced a confirmed ORR of versus ~43% for standard-of-care, with deeper responses, median PFS not yet reached for onvansertib arms, and a statistically significant benefit (p Regulatory path: Cardiff plans to advance the 30 mg dose toward a potential global registrational Phase III (considering accelerated or full approval with ORR and PFS endpoints) and expects to finalize regulatory plans and share more data in the first half of after discussions with U.S. regulators. Partner and finances: Pfizer serves as a trial partner and invested $15 million while Cardiff retains full rights, and the company reported $58.3 million in cash, which it says funds operations into Q1 2027 (excluding major Phase III spending). Interested in Cardiff Oncology, Inc.? Here are five stocks we like better. Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer's 36th Annual Healthcare Conference to highlight updated clinical results and its develop
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology (CRDF) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CRDF&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" tMarketBeat
- Cardiff Oncology to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology to Participate in Three Upcoming Investor Conferences GlobeNewswire
- Cardiff Oncology (CRDF) had its price target lowered by Piper Sandler from $10.00 to $6.00. They now have an "overweight" rating on the stock.MarketBeat
- Cardiff Oncology: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 2/24/26 - Miss
CRDF
Sec Filings
- 2/25/26 - Form 8-K
- 2/24/26 - Form 8-K
- 2/24/26 - Form 10-K
- CRDF's page on the SEC website